肺动脉高压药物治疗的新进展  

New progress in the drug treatment of pulmonary arterial hypertension

作　　者：王凯玲[1] 任涛[1] 

机构地区：[1]同济大学附属东方医院呼吸科,上海200127

出　　处：《国际呼吸杂志》2015年第10期796-800,共5页International Journal of Respiration

摘　　要：肺动脉高压（pulmonary arterial hypertension,PAH）是一种渐进性疾病,其特点为肺血管重塑,导致肺动脉压增高和右心室衰竭。近年来随着人们对 PAH 发病机制认识地不断提高,针对 PAH发病各环节的治疗均取得了长足进展,从而改变了 PAH 患者的命运。Pulmonary arterial hypertension is a progressive disease characterized by pulmonary vascular remodeling,which may lead to increased pulmonary artery pressure and right ventricular heart failure.With the increasing understanding of the pathogenesis of PAH in recent years,considerable progress has been made for the treatment of various aspects of PAH,and the fate of PAH patients has been changed.

关 键 词：肺动脉高压 药物治疗 

分 类 号：R544.1[医药卫生—心血管疾病]